Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473556 | 0.92 | DGAT1 (0.57) | DGAT1TRPV1NPC1RAB9ALMNA | |
| SCHEMBL5466732 | 0.92 | DGAT1 (0.56) | DGAT1TRPV1HTTSMN1; SMN2LMNA | |
| SCHEMBL5462739 | 0.88 | DGAT1 (0.57) | DGAT1TRPV1LMNAKDM4E | |
| SCHEMBL5471114 | 0.87 | DGAT1 (0.57) | DGAT1TRPV1NPC1RAB9AHTT | |
| SCHEMBL5451242 | 0.82 | NPC1 (0.53) | DGAT1NPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL5473462 | 0.81 | DGAT1 (0.53) | DGAT1 | |
| SCHEMBL671338 | 0.78 | DGAT1 (0.61) | DGAT1TRPV1HTTSMN1; SMN2LMNA | |
| SCHEMBL5460068 | 0.78 | DGAT1 (0.49) | DGAT1TRPV1RAB9A | |
| SCHEMBL10113239 | 0.78 | DGAT1 (0.71) | DGAT1TRPV1RAB9AHTTLMNA | |
| SCHEMBL10113578 | 0.77 | DGAT1 (0.67) | DGAT1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | DGAT1 3/4885TRPV1 4674/4885NPC1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.